欢迎您加入月均活跃用户100万+的科研社区!如您有任何系统建议,请点此洽谈。
;如有合作推广需求,请近期推荐: | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 | 新 爱思唯尔研究者学院:从初稿到接收 全程赋能 |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | Future Oncology FUTURE ONCOL (此期刊被最新的JCR期刊SCIE收录) LetPub评分 6.6
52人评分
我要评分
声誉 7.6 影响力 5.2 速度 9.1 | |||||||||||||||||||||
期刊ISSN | 1479-6694 | ![]() 蝌蝌APP,让您与同行交流更轻松
![]() | ||||||||||||||||||||
E-ISSN | 1744-8301 | |||||||||||||||||||||
2024-2025最新影响因子 (数据来源于搜索引擎) | 2.6 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2025年5月19日:2.598 | |||||||||||||||||||||
2024-2025自引率 | 0.00%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 2.8 | |||||||||||||||||||||
JCI期刊引文指标 | 0.57 | |||||||||||||||||||||
h-index | 60 | |||||||||||||||||||||
CiteScore ( 2025年最新版) |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | http://www.futuremedicine.com/loi/fon | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
期刊投稿网址 | http://www.futuremedicine.com/page/submitarticle | |||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Future Oncology的语言要求,还能让Future Oncology编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Future Oncology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(1篇) 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||
通讯方式 | FUTURE MEDICINE LTD, UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, ENGLAND, N3 1QB | |||||||||||||||||||||
出版商 | Future Medicine Ltd. | |||||||||||||||||||||
涉及的研究方向 | ONCOLOGY- | |||||||||||||||||||||
出版国家或地区 | ENGLAND | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | Monthly | |||||||||||||||||||||
出版年份 | 2005 | |||||||||||||||||||||
年文章数 | 265点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 53.16% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 74.72% | |||||||||||||||||||||
WOS期刊JCR分区 ( 2024-2025年最新版) | WOS分区等级:3区
| |||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中国科学院期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院期刊分区趋势图
| |||||||||||||||||||||
中国科学院期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||
中国科学院期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1479-6694%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 偏慢,4-8周 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Future Oncology顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(1篇) 。 提交文稿 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
中国学者近期发表的论文 | |
1. | The effect of postmastectomy radiotherapy after neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis Author: Zou, Aishan; Li, Liuyi; Guo, Yang; Zhang, Cuiwei Journal: FUTURE ONCOLOGY. 2025; Vol. 21, Issue 15, pp. 1929-1938. DOI: 10.1080/14796694.2025.2505372 PubMed DOI |
2. | rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC Author: Chi, Kim Nguyen; Mckay, Rana R.; Sandhu, Shahneen; Arranz, Jose A.; Barthelemy, Philippe; Hadaschik, Boris; Matsubara, Nobuaki; Shore, Neal D.; Ye, Dingwei; Cascella, Teresa; Irincheeva, Irina; Kreiser, Stephanie; Thiery-Vuillemin, Antoine; Rathkopf, Dana E Journal: FUTURE ONCOLOGY. 2025; Vol. 21, Issue 14, pp. 1771-1777. DOI: 10.1080/14796694.2025.2502318 PubMed DOI |
3. | Effect of PERMA-based psychological intervention and predictive care in malignant tumor patients following chemotherapy Author: Hu, Xiuying; Li, Qiuyue; Tang, Liying Journal: FUTURE ONCOLOGY. 2025; Vol. 21, Issue 13, pp. 1639-1645. DOI: 10.1080/14796694.2025.2497257 PubMed DOI |
4. | Nanoray-312: phase III study of NBTXR3+radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC Author: Le Tourneau, Christophe; Takacsi-Nagy, Zoltan; Nuyts, Sandra; Thureau, Sebastien; Liu, Feng; Hoffmann, Caroline; Hackman, Trevor G.; Lesnik, Maria; Debard, Anais; Finzi, Laetitia; Devisetty, Kiran; Vivar, Omar I.; Farber, Leonard A.; Nguyen, France; Liem, Xavier; Natelauri, Eteri; Psyrri, Amanda; Burian, Martin; Yu, Jinming; Yom, Sue S Journal: FUTURE ONCOLOGY. 2025; Vol. 21, Issue 12, pp. 1489-1499. DOI: 10.1080/14796694.2025.2496131 PubMed DOI |
5. | A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer Author: Jiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia Journal: FUTURE ONCOLOGY. 2025; Vol. 21, Issue 4, pp. 421-429. DOI: 10.1080/14796694.2024.2430106 PubMed DOI |
6. | DNAJA: emerging targets for anti-tumor therapy Author: Wu, Lige; Xing, Puyuan; Li, Junling Journal: FUTURE ONCOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2025.2514417 PubMed DOI |
7. | Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study Author: Wang, Wuping; Zhang, Pengwu; Ge, Zhenjian; Chen, Wenkang; Li, Yingqi; Lin, Shengjie; Wu, Yutong; Chen, Siwei; Zhou, Huimei; Li, Xutai; Tao, Lingzhi; Lai, Yongqing; Ni, Liangchao Journal: FUTURE ONCOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2025.2514930 PubMed DOI |
8. | Fine anatomical classification of the bronchi in left lower lobe and guidance for sublobectomy Author: Liu, Shicheng; Chen, Shuangqing; Li, Zhikai; Duan, Guochen Journal: FUTURE ONCOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2025.2514427 PubMed DOI |
9. | Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians Author: Lee, Chee Khoon; Yang, Xue; Goto, Yasushi; Lee, Kang Yun; Yim, Hyung Seok; Brooke, Mark; Aoshima, Hisakazu; Ando, Emiko; Liu, Yiting; Tsai, Jane; Low, Grace Kah Mun; Kishiwada, Naomi; Cheng, Simone Marie; Rajendran, Divashini; Gowindah, Regina; Mon, Soe Pwint Phoo; Hong, Min Hee Journal: FUTURE ONCOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2025.2499511 PubMed DOI |
10. | Effects and safety of TMZ plus RT combined with other drugs in the treatment of glioblastoma: a network meta-analysis Author: Wang, Simin; Wu, Jiyong; Zhang, Wenfei; Nie, Jing Journal: FUTURE ONCOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14796694.2025.2516408 PubMed DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室